Prime Medicine IPO
Prime Medicine is a biotechnology company developing next-generation gene editing therapies using prime editing technology. The company's platform can make precise insertions, deletions, and replacements in DNA with minimal off-target effects. Investors are attracted to its potentially superior precision compared to traditional CRISPR and its broad therapeutic applications.
What We Know
Prime Medicine completed its IPO in October 2021, raising approximately $200 million on NASDAQ under the ticker PRME. The company, co-founded by prime editing inventor David Liu, priced its shares at $17 each, generating significant interest due to its differentiated gene editing approach. Since going public, Prime Medicine has been advancing its prime editing programs through preclinical development toward clinical trials. The stock has experienced volatility typical of early-stage biotech companies, with movements often influenced by preclinical data releases and progress updates on its pipeline programs targeting various genetic diseases.
Frequently Asked Questions
Has Prime Medicine had an IPO?
Yes, Prime Medicine completed its IPO in October 2021. The company has been publicly traded on NASDAQ under the ticker PRME since then.
When is the Prime Medicine IPO date?
Prime Medicine already completed its IPO on October 21, 2021. The company is currently trading as a public biotechnology stock on NASDAQ.
How can I buy Prime Medicine stock?
You can buy Prime Medicine stock through any brokerage account since it trades publicly on NASDAQ under the ticker PRME. The shares are available for purchase during standard market hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts